Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection.

Literature DB >> 25859119

Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection.

Diana Gritsenko, Gregory Hughes.

Abstract

Ledipasvir/sofosbuvir (Harvoni): improving options for hepatitis C virus infection.

Entities: Chemical Disease

Year: 2015 PMID： 25859119 PMCID： PMC4378517

Source DB: PubMed Journal: P T ISSN： 1052-1372

15 in total

Review 1. The role of resistance in HCV treatment.

Authors: Johannes Vermehren; Christoph Sarrazin
Journal: Best Pract Res Clin Gastroenterol Date: 2012-08 Impact factor: 3.043

Review 2. Hepatitis C: diagnosis and treatment.

Authors: Thad Wilkins; Jennifer K Malcolm; Dimple Raina; Robert R Schade
Journal: Am Fam Physician Date: 2010-06-01 Impact factor: 3.292

3. Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?

Authors: Michael J Sofia
Journal: Antiviral Res Date: 2014-05-02 Impact factor: 5.970

4. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

Authors: Peter Ferenci; David Bernstein; Jacob Lalezari; Daniel Cohen; Yan Luo; Curtis Cooper; Edward Tam; Rui T Marinho; Naoky Tsai; Anders Nyberg; Terry D Box; Ziad Younes; Pedram Enayati; Sinikka Green; Yaacov Baruch; Bal Raj Bhandari; Florin Alexandru Caruntu; Thomas Sepe; Vladimir Chulanov; Ewa Janczewska; Giuliano Rizzardini; Judit Gervain; Ramon Planas; Christophe Moreno; Tarek Hassanein; Wangang Xie; Martin King; Thomas Podsadecki; K Rajender Reddy
Journal: N Engl J Med Date: 2014-05-04 Impact factor: 91.245

5. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Authors: Nezam Afdhal; Stefan Zeuzem; Paul Kwo; Mario Chojkier; Norman Gitlin; Massimo Puoti; Manuel Romero-Gomez; Jean-Pierre Zarski; Kosh Agarwal; Peter Buggisch; Graham R Foster; Norbert Bräu; Maria Buti; Ira M Jacobson; G Mani Subramanian; Xiao Ding; Hongmei Mo; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Alessandra Mangia; Patrick Marcellin
Journal: N Engl J Med Date: 2014-04-11 Impact factor: 91.245

6. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors: Jordan J Feld; Kris V Kowdley; Eoin Coakley; Samuel Sigal; David R Nelson; Darrell Crawford; Ola Weiland; Humberto Aguilar; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal: N Engl J Med Date: 2014-04-10 Impact factor: 91.245

Review 7. Antiviral activity and resistance of HCV NS5A replication complex inhibitors.

Authors: Min Gao
Journal: Curr Opin Virol Date: 2013-07-27 Impact factor: 7.090

Review 8. Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding.

Authors: Moheshwarnath Issur; Matthias Götte
Journal: Viruses Date: 2014-11-06 Impact factor: 5.048

9. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.

Authors: Edward J Gane; Catherine A Stedman; Robert H Hyland; Xiao Ding; Evguenia Svarovskaia; G Mani Subramanian; William T Symonds; John G McHutchison; Phillip S Pang
Journal: Gastroenterology Date: 2013-11-18 Impact factor: 22.682

10. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors: Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal: N Engl J Med Date: 2014-04-11 Impact factor: 91.245

26 in total

1. Silence Surrounding Hepatitis C Status in Risk Relationships Among Rural People Who Use Drugs.

Authors: Megan G Hofmeister; Jennifer R Havens; April M Young
Journal: J Prim Prev Date: 2017-10

2. Provider verification of electronic health record receipt and nonreceipt of direct-acting antivirals for the treatment of hepatitis C virus infection.

Authors: Christopher T Rentsch; Emily J Cartwright; Neel R Gandhi; Sheldon T Brown; Maria C Rodriguez-Barradas; Matthew Bidwell Goetz; Vincent C Marconi; Cynthia L Gibert; Vincent Lo Re; David A Fiellin; Amy C Justice; Janet P Tate
Journal: Ann Epidemiol Date: 2018-08-23 Impact factor: 3.797

3. Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices.

Authors: Ondrej Martinec; Martin Huliciak; Frantisek Staud; Filip Cecka; Ivan Vokral; Lukas Cerveny
Journal: Antimicrob Agents Chemother Date: 2019-10-22 Impact factor: 5.191

Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection.

Review 1. The role of resistance in HCV treatment.

Review 2. Hepatitis C: diagnosis and treatment.

3. Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?

4. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

5. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

6. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Review 7. Antiviral activity and resistance of HCV NS5A replication complex inhibitors.

Review 8. Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding.

9. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.

10. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

1. Silence Surrounding Hepatitis C Status in Risk Relationships Among Rural People Who Use Drugs.

2. Provider verification of electronic health record receipt and nonreceipt of direct-acting antivirals for the treatment of hepatitis C virus infection.

3. Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices.

Review 4. Proton Pump Inhibitors in the Elderly, Balancing Risk and Benefit: an Age-Old Problem.

5. Cohort Contributions to Race- and Gender-Specific Trends in the Incidence of Hepatocellular Carcinoma in the USA.

6. Novel symmetrical phenylenediamines as potential anti-hepatitis C virus agents.

7. The Hepatitis C virus treatment cascade at an urban postincarceration transitions clinic.

8. Investigation of the effect of verapamil on the regional absorption of sofosbuvir from rabbit intestine in situ.

Review 9. An evaluation of ledipasvir + sofosbuvir for the treatment of chronic hepatitis C infection.

10. A Schisandra-Derived Compound Schizandronic Acid Inhibits Entry of Pan-HCV Genotypes into Human Hepatocytes.